fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

In Other News...

Daviess County Traffic Advisory

DAVIESS COUNTY, Ky. (2/28/15) — A contractor for the Kentucky Transportation Cabinet plans to ramp up work zone… Read More

Pyrotechnic Event for City's Bird Control Program on Monday, March 2

OWENSBORO, Ky. (2/28/15) — In the interest of human health and safety, a pyrotechnic event, which is part of the City… Read More

Most Read This Week

February 21, 2015 7191

Traffic Advisory for Western Kentucky

in Top News For All Sites by KTC
February 25, 2015 6332

Multi-Agency Investigation Nets Large-Scale Meth…

in Top News For All Sites by Trooper Stu Recke
February 24, 2015 6225

Two Charged in Central City Meth Bust

in Local (Muhlenberg) Top News by Trooper Stu Recke
February 22, 2015 6021

Easter Cuties Pageant in Memory of Shanice Bean

in Top News For All Sites Touching Hopkins by Tammy Holloway, SurfKY News
February 25, 2015 5914

New Asian Restaurant Coming to Madisonville

in Local (Hopkins) Top News by Gary Gates, SurfKY News
February 21, 2015 5744

Local Administrators Warn Employees to Watch for…

in Top News For All Sites by Tammy Holloway, SurfKY News

Most Read This Month

February 12, 2015

UPDATE: Name of Pennyrile Fatality Officially…

in Top News For All Sites Touching Hopkins by Doreen Dennis, SurfKY News
February 09, 2015

Police Pursue Man after Fight at Taco Bell

in Local (Hopkins) Top News by Madisonville Police Department/Hopkins County Detention Center

Stories Trending Today

February 28, 2015 2251

City's Parking Ordinances to be Strictly Enforced…

in Local (Hopkins) Top News by Doreen Dennis, SurfKY News
February 27, 2015 1604

Madisonville Police Arrest Reports - Feb. 27, 2015

in Hopkins News by Madisonville Police Department
February 27, 2015 1433

Hopkins County Sheriff's Reports Released

in Hopkins News by Hopkins County Sheriff's Office
February 27, 2015 1324

Tim Thomas to Speak at Rescheduled Black History…

in Top News For All Sites Touching Hopkins by Tammy Holloway, SurfKY News
February 27, 2015 1277

AIRPLAY: Travis Dukes Makes Stop for Jam Session

in Top News For All Sites by Paul McRee, SurfKY News
February 27, 2015 1143

Local Church Hosting Spring Campmeeting

in Top News For All Sites by Gary Gates, SurfKY News
February 27, 2015 1123

Mustangs Fall to McLean County in Three Overtime…

in Local (Muhlenberg) Top News by Steve LeMaster
February 27, 2015 1090

How to Reduce Greenhouse Gas Emissions at Home

in General News For All Sites by SurfKY News
February 27, 2015 1081

Tips for Travelers Considering a Cruise

in General News For All Sites by SurfKY News
February 27, 2015 1067

Whitfield Presses Health Secretary on Obamacare…

in General News For All Sites by Marty Irby